Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

154.00
-0.3800-0.25%
Volume:3.86M
Turnover:593.81M
Market Cap:370.54B
PE:17.14
High:154.93
Open:154.90
Low:153.13
Close:154.38
Loading ...

Benadryl, Band-Aid parent says tariffs and late allergy season are hurting its business

Dow Jones
·
Yesterday

Johnson & Johnson's Darzalex Faspro Regimen Improves Progression-Free Survival in Two Phase 3 Myeloma Trials

MT Newswires Live
·
03 Jun

Johnson & Johnson announces data from two Darzalex Faspro studies

TIPRANKS
·
03 Jun

Johnson & Johnson Announces Promising Long-Term Results for CARVYKTI® in Treating Relapsed or Refractory Multiple Myeloma, Highlighting Potential for Lasting Remissions

Reuters
·
03 Jun

Johnson & Johnson Announces Promising Phase 1 Results for Novel Trispecific Antibody in Multiple Myeloma Patients

Reuters
·
03 Jun

Early Results From Johnson & Johnson's Trispecific Antibody Show Promising Response in Heavily Pretreated Multiple Myeloma Patients

THOMSON REUTERS
·
03 Jun

BRIEF-Johnson & Johnson Leads With First PARP Inhibitor Combo To Improve Efficacy In Patients With HRR-altered mCSPC

Reuters
·
03 Jun

Johnson & Johnson Launches Kincise™ 2 System, the Only Automated Surgical Impactor Approved for Knee and Hip Revision Procedures

THOMSON REUTERS
·
03 Jun

Johnson & Johnson Unveils Promising Phase 3 AMPLITUDE Study Results with Niraparib-Abiraterone Combo for Prostate Cancer, Showing Nearly 50% Reduction in Disease Progression

Reuters
·
03 Jun

Johnson & Johnson - 50% Reduction in Disease Progression in Brca-Altered Mcspc

THOMSON REUTERS
·
03 Jun

Johnson & Johnson - Phase 3 Amplitude Study Meets Primary Endpoint of Rpfs

THOMSON REUTERS
·
03 Jun

Johnson & Johnson Leads With First Parp Inhibitor Combo to Improve Efficacy in Patients With Hrr-Altered Mcspc

THOMSON REUTERS
·
03 Jun

Sanuwave Health Inc. Appoints Industry Veteran Dustin Libby as Executive VP of Commercial Operations

Reuters
·
03 Jun

Dow Falls 150 Points On Losses For 3M, Sherwin-Williams Co. Stocks

Dow Jones
·
02 Jun

TELA Bio Inc. Appoints Jeffrey Blizard as President to Propel Growth and Strengthen Leadership Team

Reuters
·
02 Jun

BRIEF-Johnson & Johnson Unveils First-In-Human Results For Pasritamig, Showing Early Anti-Tumor Activity In Prostate Cancer

Reuters
·
01 Jun

Johnson & Johnson - Data Show Low Rates of Treatment-Related Adverse Events

THOMSON REUTERS
·
01 Jun

Johnson & Johnson Unveils First-in-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer

THOMSON REUTERS
·
01 Jun

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Business Wire
·
01 Jun

5 ASX ETFs for beginners to buy in June

MotleyFool
·
31 May